SMAD4 and melanoma: Besides BRAF mutations (VAF: 40, 22.2, and 15.4%, respectively), the following aberrations were found: PIK3CA c.1031T>C, p.(Val344Ala, 13.4%) and STK11 c.1211C>T, and p.(Ser404Phe, 35.1%) in M1 melanoma case, CDKN2A c.169dup; p.(Ala57GlyfsTer63, 20.6%) and SMAD4 c.122A>G, p.(Glu41Gly, 5.7%) in M2; and, finally, APC c.3949G>C; p.(Glu1317Gln, 50%) in M3 sample (Table 3).